Home・Lista de Ações・MacroGenics Inc

MacroGenics Inc

Fechado

SetorSaúde

4.01 0.75

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.95

Máximo

4.01

Indicadores-chave
By Trading Economics
Rendimento	56M 20M
Vendas	12M 33M
EPS	-0.27
Margem de lucro	59.439
Funcionários	293
EBITDA	-34M -65M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+75% upside

Dividendos
By Acuity
Próximos Ganhos	10 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	21M 280M
Abertura anterior	3.26
Fecho anterior	4.01

Sentimento de Notícias

By Acuity

37%

63%

86 / 339 Ranking em Healthcare

MacroGenics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de set. de 2026, 20:01 UTC

MacroGenics Inc shares are higher as the market gains. Economic data showed a monthly CPI increase and a decline in consumer sentiment, yet shares advanced.

9 de set. de 2026, 20:07 UTC

News

MacroGenics Inc shares are lower amid broader market declines. The company anticipates data presentations for MGC026 and lorigerlimab at ESMO 2026.

31 de ago. de 2026, 20:02 UTC

MacroGenics Inc shares are lower today amid broader market volatility linked to potential interest rate hikes. No specific company news was identified.

20 de ago. de 2026, 20:06 UTC

MacroGenics shares are lower today, pulling back from earlier session highs amid rising crude oil prices and increased U.S. Treasury yields.

19 de ago. de 2026, 21:01 UTC

MacroGenics Inc shares are lower in after-market trading, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

18 de ago. de 2026, 19:46 UTC

MacroGenics Inc. shares are gaining during Tuesday's session, despite earlier pulling back from a session high amid rising Treasury yields and inflation concerns.

17 de ago. de 2026, 19:51 UTC

MacroGenics Inc shares are lower today amid unusual volatility, having hit a session low before a brief recovery. No specific news was identified.

14 de ago. de 2026, 19:21 UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

13 de ago. de 2026, 21:01 UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

12 de ago. de 2026, 19:46 UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

11 de ago. de 2026, 22:26 UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

4 de ago. de 2026, 19:46 UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

31 de jul. de 2026, 20:06 UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

29 de jul. de 2026, 20:09 UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

28 de jul. de 2026, 17:03 UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

27 de jul. de 2026, 20:01 UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

24 de jul. de 2026, 20:01 UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

22 de jul. de 2026, 19:51 UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 19:06 UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Comparação entre Pares

Variação de preço

MacroGenics Inc Previsão

Preço-alvo

By TipRanks

75% parte superior

Previsão para 12 meses

Média 7 USD 75%

Máximo 11 USD

Mínimo 4 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para MacroGenics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para MacroGenics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

86 / 339 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.